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Abstract 
We herein report on the application of phosphorodiamidate technology to both 
pyrimidine and purine nucleosides with anticancer activity to potentially overcome the 
resistance mechanisms associated with parent nucleosides. Sixteen symmetrical 
phosphorodiamidates prepared from natural amino acids such as L-alanine and glycine 
were synthesized. All the compounds were evaluated for their cytotoxic activity in a 
wide panel of solid and leukemic tumour cell lines. In addition, a carboxypeptidase Y 
assay was performed on a representative phosphorodiamidate in order to reveal the 
putative bioactivation pathway for the reported phosphorodiamidate-type prodrugs. 
 
Introduction 
Current chemotherapeutic treatment of cancer and viral infections is largely based on 
the use of antimetabolites, in particular modified nucleoside analogues (NA) mimicking 
natural purine or pyrimidine nucleosides.[1] In addition, there is also strong evidence 
that NAs have some potential as antibacterial agents.[2,3] These molecules are often 
taken up by nucleoside transporters (NT) and then phosphorylated by specific 
nucleo(s)(t)ide kinases to the corresponding 5’-mono, di-and triphosphate forms. These 
metabolites interfere with de novo synthesis of DNA/RNA precursors leading to 
inhibition of DNA/RNA synthesis, with subsequent suppression of tumour cell growth 
or virus replication. However, NA activity is known to be limited by mechanisms 
associated with (i) poor cellular uptake (i.e. by a down-regulation in the expression of 
nucleoside transporters), (ii) poor conversion of the drug into an active metabolite (i.e. 
by a down-regulation of nucleo(s)(t)ide kinases) or (iii) rapid degradation into toxic 
byproducts (i.e. by up-regulation of deactivating enzymes such as cytidine or cytidylate 
deaminases).[4,5] Many prodrug strategies aim to overcome such resistance mechanisms 
associated with NAs to improve the NA’s effectiveness.  These include phosphate and 
phosphonate prodrug diesters pivaloyloxymethyl (POM), 
isopropyloxycarbonyloxymethyl (POC), cyclosaligenyl (cycloSal), S-acylthioalkyl 
(SATE), lipid and HepDirect and phosphoramidates in which an amino acid ester 
promoiety is linked via P–N bond to a nucleoside aryl phosphate.[6-8] This 
monophosphate prodrug approach, also called ProTide technology, is one of the most 
successful prodrug strategies, with an established position in the nucleotide prodrug 
area. This strategy, pioneered by Chris McGuigan’s group,[9] led to the discovery and 
development of the clinically successful drugs sofosbuvir (Sovaldi)[10] and tenofovir 
alafenamide (TAF)[11] by Gilead Sciences. The first drug is approved for the treatment 
of chronic HCV infections, whereas the second to treat patients with either HIV or 
chronic HBV infections (Figure 1). Other phosphoramidates are currently the subject 
of ongoing clinical trials as antiviral agents. Stampidine is in Phase I for the treatment 
of HIV infections[12] and GS-5734, more recently developed as a treatment for filovirus 
infections,[13] was moved forward through a Phase I clinical trial[14] as a consequence 
of the Ebola outbreak in West Africa in 2013-2016.[15] GS-9131 is an orally bioavailable 
phosphonoamidate prodrug which has been shown to inhibit HIV-1 reverse 
transcriptase (RT) in multiple HIV-1 clinical subtypes and has a unique resistance 
profile toward N(t)RTI resistance mutations. GS-9131 is currently under clinical 
evaluation.[16]  
In the oncology arena, the first phosphoramidate to reach the clinic was 
thymectacin (NB1011) which was evaluated in a Phase I trial for the treatment of colon 
cancer.[17] Subsequently, our group designed and synthesised two phosphoramidate 
prodrugs named NUC-1031[18-20] and NUC-3373[21-23] (Figure 1).  The gemcitabine 
phosphoramidate NUC-1031 is currently being evaluated in several clinical studies, 
including a Phase III study for patients with pancreatic cancer, a Phase II study for 
patients with ovarian cancer and a Phase Ib study for patients with biliary tract cancers. 
The 5’-fluoro-2’-deoxyuridine (FUdR) ProTide NUC-3373 is currently being evaluated 
in a Phase I study for the treatment of a variety of solid tumours including colorectal 
and breast cancers.  
  
Figure 1. ProTides of antiviral and anticancer nucleoside monophosph(on)ate 
analogues that have entered clinical studies. 
 
Although less extensively investigated than the ProTide approach, a second 
phosphoramidate strategy that has been reported by our group as a promising way for 
the delivery of nucleoside monophosphates inside the cell, is the phosphorodiamidate 
technology.[24-26] In this approach, two identical amino acid esters are introduced on the 
monophosphate moiety through a P–N bond in order to mask the negative charges. Due 
to their symmetric structure, phosphoro(no)amidates, where no phosphorus chirality 
arises, offer advantages over the aryloxy monoamidate analogues. 
Although stereoisomers have the same chemical structure they may exhibit 
differences in their pharmacology, toxicology, pharmacokinetics and metabolism. For 
example, the Sp diastereoisomer of TAF is 10-fold more potent against HIV than the 
Rp diastereoisomer.[27] Likewise, in the HCV replicon assay, the Sp and Rp isomers of 
sofosbuvir demonstrated an approximately 18-fold difference in activity against 
HCV.[28] Though separation of the ProTide diastereoisomers by crystallization or by 
chromatography can be achieved in some cases,[29,30] and different approaches to obtain 
ProTides in a diastereoselective[31-34]  and 5’-regioselective fashion[35] have been 
recently reported, in general most of these methodologies are not very efficient and are 
high-priced, time consuming and difficult to scale up. In this scenario the diamidate 
approach, if as effective as the ProTides in terms of activity, could be considered as a 
valid alternative, as demonstrated by 2’-C-methyl-6-O-methylguanosine-based 
phosphorodiamidate agents and their nanomolar anti-HCV activity in replicon assay.[24] 
Although the diamidate prodrug approach has been validated both in vitro and in vivo, 
to our knowledge, only one phosphonodiamidate, GS-9191 (Figure 1), has reached the 
clinic to date. GS-9191 is a nucleotide analogue under clinical evaluation as a topical 
ointment in patients with external genital and perianal warts caused by human 
papilloma virus infection.[36] 
Based on our preliminary findings,[24-26] considering the potential advantage of 
lack of chirality at the phosphorus atom for this class of prodrugs, and taking into 
account the extraordinary results obtained with gemcitabine and FUdR ProTides, we 
were interested to investigate the potential of the phosphorodiamidate approach when 
applied to these two nucleosides. We also took the opportunity to expand our study to 
other relevant anticancer NAs (1-7, Figure 2).  
Herein, we report the synthesis, and biological activities of these target 
compounds (8-23) against a wide panel of cancer cell lines. Moreover, in order to 
support a putative bioactivation pathway for these prodrugs (in particular regarding the 
first activation step), we also report on carboxypeptidase Y assays for the gemcitabine 
phosphorodiamidate 8. 
 Figure 2. Anticancer nucleosides considered for this study. 
 
Results and discussion 
Chemistry 
The phosphorodiamidate prodrugs of gemcitabine (1), FUdR (2), 
8-chloroadenosine (3), fludarabine (4), AraG (5), thioinosine (6-MP, 6), and 
thioguanosine (6-TG, 7), were prepared according to reported procedure.[37] This 
modified method, based on a Yoshikawa procedure to synthesize monophosphate 
species,[38] was successfully applied previously to a number of antiviral and anticancer 
nucleosides and led to identification of phosphorodiamidates, with L-alanine bearing 
either benzyl or 2,2-dimethoxypropyl as the most promising compounds. [24-26] Thus, in 
this work, we selected the above-mentioned amino acid esters as preferred entities and 
synthesized in total sixteen phosphorodiamidate prodrugs of seven anticancer NAs. 
Moreover, for gemcitabine and FUdR, cyclohexyl, pentyl and cyclopentyl esters were 
also used, since these moieties afforded molecules with low submicromolar anticancer 
activity when applied in the ProTide approach.[18,19] Additionally, for 8-
chloroadenosine, another natural amino acid such as glycine was also included. In the 
first step of a general one-pot-two-stages strategy, unprotected nucleoside analogue was 
treated with trimethylphosphate (TMP) and 1 equivalent of POCl3, leading to the 
formation of the phosphorodichloridate intermediate as depicted in Scheme 1, the 
formation of the latter intermediate (not isolated) was monitored by 31P NMR (δp = ~ 
7-8 ppm) and was accomplished within 4-12 hours. Following this, addition of the 
appropriate amino acid ester salt (5 equiv.) in the presence of DIPEA (10 equiv.) at –
78 °C afforded the desired phosphorodiamidates 8-23 with the yields between 3% and 
49%. 
 
Scheme 1. General synthetic route to phosphorodiamidates 8-23. Reagents and 
conditions: (a) (Me)3PO4 (1 mL), POCl3 (2 equiv.), 0-5 C, 16 h, (b) anhydrous DCM, 
amino acid ester salt (5 equiv.), DIPEA (10 equiv.), -78 C (30 min.), then 0-5 C, 72h. 
 
Anticancer Activity 
The anti-proliferative activities of nucleoside analogues and their related 
phosphorodiamidates derived from gemcitabine (1; 8-10), FUdR (2; 11-14), 
8-chloroadenosine (3; 15, 16), fludarabine (4, 17, 18), AraG (5; 19), 6-MP (6; 20, 21), 
6-TG (7; 22, 23) are represented by their absolute EC50 (ȝM) and maximal inhibition at 
the highest compound concentration (%) and are reported in Table 1 (solid tumour cell 
lines) and Table 2 (hematologic cell lines).  Gemcitabine was found to be the most 
effective compound in Mia-Pa-Ca-2 cell cultures at an EC50 of 1.04 ȝM. However, its 
prodrugs 8-10 were shown to be less active with EC50 ranging between 1.45-7.68 ȝM. 
In the same cell line, such loss of activity was also observed for the diamidates of FUdR 
2, with the prodrugs 11 and 13 showing EC50 of 3.54 ȝM and 57.77 ȝM, respectively, 
versus an EC50 of 0.18 ȝM for the nucleoside 2. Conversely, the diamidate of 8-ClA 16 
showed a 2-fold increase in anticancer potency compared with the parent compound 3 
in the Mia-Pa-Ca-2 cell line. A similar trend and a 2-fold boost in activity for prodrug 
over nucleoside analogue were noticed for 8-ClA 3 and the phosphorodiamidate 16 in 
the MCF-7 cell line, which is generally (along with HepG2) the least sensitive tumour 
cell line to our tested compounds. In a panel of leukemia cell lines, while AraG 5 
showed micromolar activity (EC50 of 1.35 ȝM for CCRF-CEM and 1.7λ ȝM for 
MOLT-4), its phosphorodiamidate 19 was found ineffective (>1λ8 ȝM) in the same 
cancer cell lines. This may be suggestive of a poor cellular uptake and/or metabolic 
bioactivation and conversion of the phosphorodiamidate 19 into the corresponding 
nucleoside monophosphate form. The cytostatic activities of 6-MP 6 and 6-TG 7 were 
similar at submicromolar level (for 6: EC50 of 0.64 ȝM in CCRF-CEM and 0.83 ȝM in 
MOLT-4; for 7: EC50 of 0.71 ȝM in HL-60). The two L-Ala-OBn phosphorodiamidates 
20 and 22 were 3-fold less active than the parent 6 and 5-fold less active than the 
parent 7, respectively. A similar trend was noted for the two L-Ala-Oneopentyl prodrugs 
21 and 23, however with markedly higher loss of activity in respect to the nucleosides 
6 and 7 (55-fold in CCRF-CEM, 46-fold in MOLT-4 for 21; 54-fold in HL-60 for 23). 
This was also observed for AraG phosphorodiamidate 19. Thus, as already mentioned 
above, the significant reduction of potency of the prodrugs containing the neopentyl 
ester may indicate either poor cellular uptake and/or metabolic activation and/or higher 
susceptibility of L-Ala-Oneopentyl phosphorodiamidates as well as their metabolites to 
drug efflux pumps.[22] Generally, the maximal inhibition observed at the highest 
compound concentration (1λ8 ȝM) for all tested compounds ranged between 7λ-100% 
except for 19, the diamidate of AraG (22% in CCRF-CEM and 25% in MOLT-4).  
  
Table 1. aEC50 (ȝM) and Max Inhibition (%) (MI%) of selected phosphorodiamidates 
for solid tumour cell lines. 
 
 
aEC50 Values (50% effective concentration on inhibition of cell viability), and MI(%) 
(maximum inhibitory effect of the drug at the range of concentration considered). The 
compounds were added to the cell in duplicate and tested in 9 serial concentrations from 
198 M to 0.0199 M. 
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MCF-7 HepG2 HT2
9 
 Mia-Pa-Ca-2 
EC50  MI% 
 
EC50 MI% 
 
EC50 MI% 
 
EC50 MI% 
 
 
Gem 
 
1 
    
>198 
 
51 
 
51.98 
 
50 
 
2.23 
 
57 
 
1.04[18] 
 
80 
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L-Ala 
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52 
 
>198 
 
39 
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47 
 
1.45 
 
74 
 
9 
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L-Ala 
 
CH2tB
u 
  
>198 
 
49 
 
178.12 
 
55 
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54 
 
7.68 
 
75 
 
10 
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L-Ala 
 
cHex 
  
>198 
 
51 
 
>198 
 
53 
 
70.54 
 
56 
 
4.48 
 
77 
 
NUC-1031 
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L-Ala 
 
Bn 
 
Ph 
 
- 
 
- 
 
- 
 
- 
 
2.89 
 
- 
 
0.44[18] 
 
- 
 
FUdR 
 
2 
 
 
 
 
 
 
 
9.82 
 
78 
 
94.16 
 
65 
 
0.20 
 
84 
 
0.18 
 
90 
 
11 
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L-Ala 
 
CH2tB
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52 
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25 
 
8.58 
 
78 
 
3.54 
 
82 
 
12 
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L-Ala 
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13 
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L-Ala 
 
cPnt 
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48 
 
>198 
 
38 
 
>198 
 
47 
 
57.77 
 
74 
 
14 
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L-Ala 
 
Bn 
  
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
NUC-3373 
 
2 
 
L-Ala 
 
Bn 
 
Naph 
 
- 
 
- 
 
- 
 
- 
 
0.42 
 
91 
 
- 
 
- 
 
8-ClA 
 
3 
 
 
 
 
 
 
 
2.15 
 
74 
 
0.79 
 
82 
 
0.87 
 
79 
 
1.0 
 
93 
 
15 
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L-Ala 
 
Bn 
 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
16 
 
3 
 
Gly 
 
Bn 
  
1.08 
 
87 
 
1.24 
 
87 
 
1.64 
 
87 
 
0.52 
 
94 
Table 2. aEC50 (ȝM) and Max Inhibition (%) (MI%) of selected phosphorodiamidates 
for hematologic cell lines. 
 
aEC50 Values (50% effective concentration on inhibition of cell viability) and MI(%) 
(maximum inhibitory effect of the drug at the range of concentration considered). The 
compounds were added to the cell in duplicate and tested in 9 serial concentrations from 
198 M to 0.0199 M. 
 
The IC50 values of FUdR, 8-ClA and fludarabine and their respective 
phosphorodiamidates versus mouse lymphocytic leukemia (L1210), human CD4+ 
T-lymphocyte cells (CEM), and human cervical carcinoma (HeLa) cells are reported in 
Table 3. FUdR (2) and its phosphorodiamidate prodrugs (11-14) showed activity in a 
submicromolar range with IC50 of 0.0046-0.073 ȝM for FUdR and 0.01-0.40 ȝM for 
the FUdR phosphorodiamidates against the wild-type cell lines. The L-alanine pentyl 
prodrug 12 proved ~2-fold more active against HeLa cell cultures and ~2-fold less 
active against L1210 and CEM cell cultures than FUdR. The loss of inhibitory activity 
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EC50 MI% 
 
EC50 MI% 
 
 
8-ClA 
 
3 
   
0.46 
 
89 
 
0.53 
 
99 
 
0.52 
 
96 
 
0.52 
 
99 
 
16 
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Gly 
 
Bn 
 
0.41 
 
93 
 
0.5 
 
100 
 
0.35 
 
96 
 
0.39 
 
100 
 
AraG 
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1.35 
 
101 
 
1.79 
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- 
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- 
 
19 
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L-Ala 
 
CH2tBu 
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22 
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25 
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6-MP 
 
6 
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98 
 
0.83 
 
100 
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20 
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L-Ala 
 
Bn 
 
1.85 
 
98 
 
2.58 
 
99 
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21 
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L-Ala 
 
CH2tBu 
 
35.4 
 
76 
 
38.5 
 
84 
 
- 
 
- 
 
- 
 
- 
 
6-TG 
 
7 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
0.71 
 
95 
 
22 
 
7 
 
L-Ala 
 
Bn 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
3.70 
 
92 
 
23 
 
7 
 
L-Ala 
 
CH2tBu 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
38.6 
 
79 
  
          
for compound 14 versus FUdR ranged between 3-13-fold, and for compound 11 
between ~3-15-fold.  
The cytostatic activity of FUdR strongly depends on the thymidine kinase (TK) 
enzyme responsible for the first phosphorylation step of FUdR to FdUMP. Therefore 
the marked loss of activity for 2 was expected in the TK-deficient tumour cell lines and 
was 10-fold against HeLa/TK-, 100-fold against CEM/TK- and 217-fold against 
L1210/TK-. Although the potency of the four FUdR phosphorodiamidates was also 
diminished in the TK-deficient tumour cell lines, the difference in fold- reduction was 
less dramatic (11- to 51-fold instead of 217-fold for the parent FUdR). 
However, for the CEM/TK- and HeLa/TK- cell lines the loss in activity found for the 
FUdR phosphorodiamidates 11-14 was significantly higher than for FUdR. These data 
clearly indicate that the phosphorodiamidates 11-14 require TK to eventually exert 
biological activity, as they most likely release FUdR instead of the desired 5'-
monophosphate metabolite FdUMP. Strikingly, the cytostatic activity spectrum of L-
Ala-OBn-ONaph substituted FUdR prodrug, NUC-3373, that is not a 
phosphorodiamidate but contains the traditional ProTide structure, clearly differed 
from the phosphorodiamidate prodrugs. NUC-3373 not only showed pronounced 
cytostatic activity against the wild-type tumour cells (IC50: 0.011-0.068 ȝM), but it 
remarkably retained considerable cytostatic potential against the TK-deficient tumour 
cell lines, in particular for the L1210/TK- and CEM/TK- cell lines.   
The drugs 3 and 4 along with their phosphorodiamidates 15, 16, 17 and 18 were also 
investigated. Unlike for FUdR, TK activity is not a prerequisite for 8-Cl-adenosine and 
fludarabine. 8-Cl-adenosine and fludarabine showed micromolar IC50 and both were 
more active than their phosphorodiamidates. However, the difference in activity was 
less significant in case of the 8-chloroadenosine series with the benzyl L-alanine 
diamidate 15 being 2.6-3.4-fold less active than parent nucleoside 3. The benzyl glycine 
diamidate 16 was found to be only ~1-5 to 2-fold less active than the parent 
8-chloroadenosine. 
 
Table 3. Cytostatic Activity (aIC50 in ȝM) reported for FUdR (2), 8-chloroadenosine 
(3) and fludarabine (4), and phosphorodiamidate prodrugs (11-14, 15, 16, 17 and 18) 
against tumour cell lines. 
 
  
 
Comp 
 
 
NA 
 
 
AA 
 
 
Ester  
(R3) 
 
 
Ar 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 IC50 (M)      
L1210 L1210/ 
TK- 
 
Ratio 
TK+/TK- 
CEM CEM/ 
TK- 
Ratio 
TK+/TK- 
HeLa HeLa/  
TK- 
 
Ratio 
TK+/TK- 
  
            
FUdR 
 
 
2    0.0046 
0.0027 
1.00.3 217 0.013
0.008 
1.30.1 100 0.073
0.032 
0.73 
0.16 
10 
11 
 
 
2 L-Ala CH2tBu  0.069 
0.006 
0.760.06 11 0.16 
0.11 
158 94 0.19 
0.03 
646 337 
12 
 
 
2 L-Ala Pnt  0.01 
0.001 
0.470.0 47 0.028
0.019 
4.21.0 150 0.037
0.029 
3.41.1 92 
13 
 
 
2 L-Ala cPnt  0.16 
0.01 
2.50.1 16 0.24 
0.02 
5621 233 0.4 
0.05 
689 170 
14 2 L-Ala Bn  0.045 
0.013 
 
2.30.6 51 0.17 
0.07 
388 223 0.24 
0.05 
168 67 
NUC-3373 
 
 
2 L-Ala Bn Naph 0.011 
0.007 
0.045 
0.027 
4 0.068
0.035 
0.31 
0.06 
4 0.065
0.013 
2.51.3 38[19] 
8-ClA 
 
 
3    3.20.7 - - 1.10.6 - - 0.89 
0.5 
- - 
15 3 L-Ala Bn  104 - - 3.80.2 - - 2.31.0 - - 
16 3 Gly Bn  4.60.0 - - 3.40.4 - - 1.80.4 - - 
Fludarabine 4    119 - - 2.11.4 - - 8.03.3 - - 
17 4 L-Ala CH2tBu  5536 - - 152 - - 473 - - 
18 4 L-Ala Bn  325 - - 1614 - - 2411 - - 
  
            
  
 
 
 
 
 
 
 
 
 
aIC50 or compound concentration required to inhibit tumour cell proliferation by 50%. 
Data are the mean  (SD) of at least two to four independent experiments.   
 
Enzymatic Studies 
The general putative mechanism of the bioactivation pathway for 
phosphorodiamidates is depicted in Scheme 2 and is similar to the metabolic route 
postulated for the phosphoramidates[39,40] involving four (a-d) consecutive steps: a) 
esterase or carboxypeptidase-mediated hydrolysis of one of the two esters; b) 
spontaneous intracellular displacement of the second amino acid through an 
intramolecular attack of the carboxylate anion on the phosphorus and further formation 
of a mixed five-membered ring anhydride; c) spontaneous hydrolysis of the anhydride 
intermediate; and finally d) P–N bond cleavage mediated by a phosphoramidase-type 
enzyme.[41,42] 
 
 
Scheme 2. General putative activation pathway of phosphorodiamidate prodrugs: a) 
carboxypeptidase-mediated ester hydrolysis; b) spontaneous intracellular 
displacement; c) spontaneous hydrolysis; d) enzyme-mediated P–N bond cleavage. 
 
Here, we report the carboxypeptidase Y assay performed on the gemcitabine 
phosphorodiamidate 8 in the presence of d6-acetone and TRIZMA buffer (pH = 7.6), 
showing ester hydrolysis of one of the amino acid ester moieties during the 
bioactivation process. Upon the addition of carboxypeptidase Y, within the first 
10 minutes of incubation, phosphorodiamidate 8 (δp = 14.14 ppm, Figure 2) was 
converted to the intermediate 8-A lacking both ester moieties (peak at 14.82 ppm). 
Finally, the formation of the metabolite 8-C lacking one of the amino acid (thought to 
be mediated by spontaneous cyclisation and hydrolysis) (8-B) was confirmed by the 
presence of the single peak at δp 7.04 ppm. This is analogous to results reported in our 
previous study.[24] No direct 31P-NMR evidence was obtained for the formation of the 
cyclic compound 8-B, consistent with it being a short-lived metabolite. Another 
possibility could be that the metabolite 8-C is formed spontaneously from the 
metabolite 8-A, without a cyclisation step being involved. Compound 8 was fully 
processed to the aminoacyl metabolite 8-C within approximately 3 h, with an estimated 
half-life of 6 minutes. 
 
  
Scheme 3. Putative mechanism of bioactivation for phosphorodiamidate 8. 
 
The same activation pathway with a similar estimated half-life was obtained with 
inactive compound 18, the phosphorodiamidate of AraG (data not shown). These 
results indicate that discrimination between active and inactive compounds might be 
ascribed to the last step in the activation pathway, catalysed by Hint, a phosphoramidase 
type enzyme.[41-43] 
 
  
Figure 3. Carboxypeptidase Y-mediated cleavage of compound 8 as monitored by 31P NMR. 
 
 
Conclusion 
In conclusion, we report on the application of the phosphorodiamidate approach 
leading to sixteen prodrugs derived from amino acids and seven anticancer nucleoside 
analogues. The biological in vitro screening of the phosphorodiamidates against a wide 
panel of tumour cell lines revealed a potential of this approach in case of FUdR and 8-
ClA, since some of their corresponding phosphorodiamidate prodrugs showed similar 
or improved inhibitory activities when compared with the parent nucleosides. The 
carboxypeptidase Y assay supported the postulated bioactivation pathway as reported 
for one gemcitabine phosphorodiamidate 8, for which a similar activity versus its parent 
compound was observed for the Mia-Pa-Ca-2 tumour cell line. The lack of activity 
found in the other families of compounds may indicate either poor bioactivation of the 
phosphorodiamidate motif with a subsequent poor release of the free 5’-monophosphate 
form (last step) or susceptibility of inactive phosphorodiamidates and their 
corresponding metabolites to drug efflux pump mechanisms. Overall, the wide range 
of in vitro data presented for the selected phosphorodiamidates may demonstrate that 
the biological properties and activities of nucleoside analogues and their prodrugs are 
unpredictable due to the complexity of the nature of distinct cell systems and 
differences in levels and activity of enzymes involved in the uptake and conversion of 
the prodrugs to the eventual intracellular active metabolite.  
 
Experimental Section 
MTS Cell Viability Assay. The solid and hematologic tumour cell lines were seeded 
at a range of density 0.5 to 100 x 103 cells/well in the wells of a 96-well plate the day 
before compound incubation, then incubated for 72 hours with the different 
concentrations of the test compound. Then 50 L of MTS was added and the cells were 
incubated for 4 h at 37 C. The data were read and collected by a Spectra Max 340 
Absorbance Microplate Reader. The compounds were tested in duplicate with 9 serial 
concentrations (3.16-fold titrations with 1λ8 ȝM as the highest concentration), and the 
data were analyzed by XL-fit software. 
Cell cultures and Cytostatic Activity Assays. Murine leukemia L1210, human 
lymphocyte CEM, human cervix carcinoma HeLa and their corresponding 
TK-deficient congeners L1210/TK-, CEM/TK- and HeLa/TK- were seeded at –50 to 75 
x 103 cells/200 µl in the wells of a 96-well microtiter plate that contained a variety of 
drug concentrations. After 48 hours (L1210) or 72-96 hours (CEM; HeLa) the cell 
number was determined by counting with a Coulter Counter. The IC50 (50% inhibitory 
concentration) was determined as the drug concentration required to inhibit tumor cell 
proliferation by 50%. 
Carboxypeptidase Y (EC 3.4.16.1) Assay. The experiment was carried out by 
dissolving diamidate 8 (5.0 mg) in acetone-d6 (0.15 mL) followed by addition of 
0.30 mL of Trizma buffer (pH 7.6). After recording the control 31P NMR at 25 C, a 
previously defrosted carboxypeptidase Y (0.1 mg dissolved in 0.15 mL of Trizma) was 
added to the sample, which was then immediately submitted to the 31P NMR analysis 
(at 25 C). The spectra were recorded every 7 minutes for over 14 hours. 31P NMR 
recorded data were processed and analyzed with the Bruker Topspin 2.1 program.  
 
Chemistry. General Procedures. Solvents and Reagents. The following anhydrous 
solvents were purchased from Sigma-Aldrich: dichloromethane (CH2Cl2), 
trimethylphosphate ((Me)3PO4), triethylphosphate ((Et)3PO4), diethyl ether (Et2O), 
tetrahydrofuran (THF), dimethylformamide (DMF), and any other reagents used. 
Amino acid esters commercially available were purchased from Novabiochem. All 
reagents commercially available were used without further purification. 
Thin Layer Chromatography (TLC). Precoated aluminium-backed plates (60 F254, 
0.2 mm thickness, Merck) were visualized under both short and long wave ultraviolet 
light (254 and 366 nm) or by burning using the following TLC indicators: (i) molybdate 
ammonium cerium sulfate; (ii) potassium permanganate solution. Preparative TLC 
plates (20 cm × 20 cm, 500-2000 ȝm) were purchased from Merck. 
Flash Column Chromatography. Flash column chromatography was carried out 
using silica gel supplied by Fisher (60A, 35-70 ȝm). Glass columns were slurry packed 
using the appropriate eluent with the sample being loaded as a concentrated solution in 
the same eluent or pre-adsorbed onto silica gel. Fractions containing the product were 
identified by TLC, and pooled and the solvent was removed in vacuo. 
High Performance Liquid Chromatography (HPLC). The purity of the final 
compounds was verified to be >95% by HPLC analysis using either I) 
ThermoSCIENTIFIC, SPECTRA SYSTEM P4000, detector SPECTRA SYSTEM 
UV2000, Varian Pursuit XRs 5 C18, 150 x 4.6 mm (as an analytic column) or II) Varian 
Prostar (LC Workstation-Varian Prostar 335 LC detector), Thermo SCIENTIFIC 
Hypersil Gold C18, 5 m, 150 x 4.6 mm (as an analytic column). For the method of 
elution see the experimental part. The purification of one final compound was achieved 
on Pursuit XRs 5 C18, 150 x 21.2 mm (as the semi-preparative column), Varian Prostar 
(LC Workstation-Varian Prostar 335 LC detector).   
Nuclear Magnetic Resonance (NMR). 1H NMR (500 MHz), 13C NMR (125 MHz), 
31P NMR (202 MHz) and 19F NMR (470 MHz) were recorded on a Bruker Avance 
500 MHz spectrometer at 25 ºC. Chemical shifts (δ) are quoted in parts per million 
(ppm) relative to internal CH3OH-d4 (δ 3.34 1H-NMR, δ 49.86 13C-NMR) and CHCl3-
d4 (δ 7.26 1H NMR, δ 77.36 13C NMR) or external 85 % H3PO4 (δ 0.00 31P NMR). 
Coupling constants (J) are measured in Hertz. The following abbreviations are used in 
the assignment of NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet), bs (broad singlet), dd (doublet of doublet), dt (doublet of triplet), app 
(apparent). The assignment of the signals in 1H NMR and 13C NMR was done based on 
the analysis of coupling constants and additional two-dimensional experiments (COSY, 
HSQC, HMBC, PENDANT).  
Mass spectromethry (MS). Low resolution mass spectra were performed on Bruker 
Daltonics microTof-LC, (atmospheric pressure ionization, electron spray mass 
spectroscopy) in either positive or negative mode.  
Standard procedure A: synthesis of phosphorodiamidates. To a solution of 
nucleoside (1 eq) in trimethyl phosphate (1 mL per 1 mmol of nucleoside, unless 
otherwise stated), phosphoryl chloride (1-2 eq) was added dropwise at - 5 C and the 
reaction mixture was left stirring for 4 - 12 hours. The formation of the intermediate 
was monitored by 31P-NMR. A suspension of the appropriate amino acid ester (5 eq) in 
dichloromethane (4 mL per 1 mmol of amino acid ester) was added followed by 
diisopropyl ethyl amine (10 eq) at - 78 C. After stirring at room temperature for 
20 hours, water (10 mL per mmol of nucleoside) was added and the layers were 
separated. The aqueous phase was extracted with CH2Cl2 (10 mL per mmol of 
nucleoside) and the organic phase washed with brine (10 mL per mmol of nucleoside). 
The combined organic layers were dried over Na2SO4 and concentrated. The residue 
was purified unless otherwise stated either by column chromatography or Biotage 
Isolera One to give the title compound as a white solid.  
 
2’-Deoxy-2’,2’-difluoro-D-cytidine-5’-O-bis(benzoxy-L-alaninyl)] phosphate (8): 
Prepared according to the standard procedure A from gemcitabine (0.25 g, 0.95 mmol), 
POCl3 (0.29 g, 0.17 mL, 1.89 mmol), followed by addition of L-Ala benzyl ester 
tosylate salt (1.67 g, 4.75 mmol), DIPEA (1.23 g, 1.65 mL, 9.50 mmol). Column 
purification followed by preparative TLC purification gave the product 8, as a white 
solid (0.079 g, 12%). 31P NMR (202 MHz, CD3OD)μ δ = 13.87; 19F NMR (470 MHz, 
CD3OD)μ δ = – 118.14 (d, J = 239 Hz), –119.70 (d, broad signal, J = 239 Hz); 1H NMR 
(500 MHz, CD3OD)μ δ = 7.67 (d, J = 7.53 Hz, 1H, H-6), 7.38 – 7.31 (m, 10H, H-Ar), 
6.27 (t, J = 8.05 Hz, 1H, H-1’), 5.97 (d, J = 7.51 Hz, 1H, H-5), 5.18 – 5.10 (m, 4H, 2 x 
CH2Ph), 4.31 – 4.17 (m, 3H, H-5’, H-3’, H-5’), 4.02 – 3.95 (m, H-4’, 3H, 2 x 
NHCHCH3), 1.38 (d, J = 7.14 Hz, 3H, NHCHCH3), 1.36 (d, J = 7.14 Hz, 3H, 
NHCHCH3); 13C NMR (125 MHz, CD3OD)μ δ = 175.43 (d, 3JC-P = 5.40 Hz, C=O, 
ester), 167.68 (C-2), 157.81 (C-4), 142.63 (C-6), 137.29, 137.28 (C-Ar), 129.85, 
129.66, 129.65, 129.40, 129.39, 129.32, 127.02 (CH-Ar), 123.69 (apparent t, 1JC-F = 
258 Hz, CF2), 96.87 (C-5), 86.02 (apparent t, broad signal, 2JC-F = 27.0 Hz, C-1’), 80.46 
(apparent t, 3JC-F = 8.20 Hz, C-4’), 71.28 (apparent t, 2JC-F = 23.44 Hz, C-3’), 68.00, 
67.99 (CH2Ph), 64.52 (d, 2JC-P = 4.78 Hz, C-5’), 51.15 (d, 2JC-P = 5.41 Hz, NHCHCH3), 
20.78, 20.67 (2 x d, 3JC-P = 5.53 Hz, NHCHCH3); MS [ES+] m/z: found 666.22 [M + 
H+], 688.21 [M + Na+], C29H34F2N5O9P required 665.58 [M]. HRMS [ESI] m/z: 
calculated for C29H34F2N5O9P: 665.2062; found 666.2058 [M + H]+. Reverse-phase 
HPLC eluting with H2O/CH3OH from 100/0 to 0/100 in 35 min), F = 1 mL/min, Ȝ = 
254, tR = 24.15 min. 
 
2’-Deoxy-2’,2’-difluoro-D-cytidine-5’-O-bis(2,2-dimethylpropoxy-L-alaninyl)]-
phosphate (9): Prepared according to the standard procedure A from gemcitabine (0.25 
g, 0.95 mmol), POCl3 (0.29 g, 0.17 mL, 1.89 mmol), and (Et)3PO (1.0 mL), followed 
by addition of L-Ala neopentyl ester tosylate salt (1.57 g, 4.75 mmol), DIPEA (1.23 g, 
1.65 mL, 9.50 mmol). Column purification followed by preparative TLC purification 
gave the compound 9 as a white solid (0.041 g, 7%); 31P NMR (202 MHz, CD3OD)μ δ 
= 13.93; 19F NMR (470 MHz, CD3OD)μ δ = –118.1 (d, J = 245 Hz), –119.6 (d, J = 245 
Hz); 1H NMR (500 MHz, CD3OD): δ = 7.70 (d, J = 7.58 Hz, 1H, H-6), 6.29 (t, J = 8.20 
Hz, 1H, H-1’), 6.01 (d, J = 7.58 Hz, 1H, H-5), 4.37 – 4.33 (m, 1H, H-5’), 4.30 – 4.23 
(m, 2H, H-5’, H-3’), 4.08 – 4.06 (m, 1H, H-4’), 4.03 – 3.96 (m, 2H, 2 x NHCHCH3), 
3.90, 3.93 (AB system, JAB = 10.55 Hz, 2H, CH2C(CH3)3), 3.79, 3.73 (AB system, JAB 
= 11.0 Hz, 2H, CH2C(CH3)3), 1.45 (d, J = 7.08 Hz, 3H, NHCHCH3), 1.43 (d, J = 7.08 
Hz, 3H, NHCHCH3), 0.97 (s, 18H, 2 x CH2C(CH3)3); 13C NMR (125 MHz, CD3OD): 
δ
 
= 175.71 (d, 3JC-P = 3.44 Hz, C=O, ester), 175.67 (d, 3JC-P = 3.44 Hz, C=O, ester), 
167.70 (C-2), 157.79 (C-4), 142.68 (C-6), 123.65 (apparent t, 1JC-F = 258 Hz, CF2), 
96.84 (C-5), 86.04 (apparent t, 2JC-F = 26 Hz, C-1’), 80.48 (apparent t, 3JC-F = 8.51 Hz, 
C-4’), 75.46, 75.43 (CH2C(CH3)3), 71.30 (t, 2JC-F = 23.0 Hz, C-3’), 64.57 (d, 2JC-P = 
4.73 Hz, C-5’), 51.17 (d, 2JC-P = 7.78 Hz, NHCHCH3), 32.35 (CH2C(CH3)3), 32.33 
(CH2C(CH3)3), 26.7 (CH2C(CH3)3), 21.08 (d, 3JC-P = 6.10 Hz, NHCHCH3), 20.96 (d, 
3JC-P = 6.10 Hz, NHCHCH3); MS [ES+] m/z: found 626.28 [M + H+], 648 [M + Na+], 
C25H42F2N5O9P required 625.60 [M].  Reverse-phase HPLC eluting with H2O/CH3CN 
from 100/0 to 0/100 in 35 min), F = 1 mL/min, Ȝ = 254, tR = 17.27 min. 
 
2’-Deoxy-2’,2’-difluoro-D-cytidine-5’-O-bis(cyclohexoxy-L-alaninyl)]-phosphate 
(10): Prepared according to the standard procedure A from gemcitabine (0.25 g, 0.95 
mmol), POCl3 (0.29 g, 0.17 mL, 1.89 mmol), followed by addition of L-Ala cyclohexyl 
ester HCl salt (0.99 g, 4.75 mmol), DIPEA (1.23 g, 1.65 mL, 9.50 mmol). Column 
purification followed by preparative TLC purification gave the product 10, as a white 
solid (0.029 g, 5%); 31P NMR (202 MHz, CD3OD)μ δ = 13.94; 19F NMR (470 MHz, 
CD3OD)μ δ = –118.30 (d, J = 241 Hz), –119.78 (d, broad signal, J = 245 Hz); 1H NMR 
(500 MHz, CD3OD)μ δ = 7.70 (d, J = 7.15 Hz, 1H, H-6), 6.29 (t, J = 7.97 Hz, 1H, H-
1’), 6.01 (d, J = 7.51 Hz, 1H, H-5), 4.79 – 4.73 (m, 2H, 2 x OCH-cyclohexyl), 4.37 – 
4.33 (m, 1H, H-5’), 4.32 – 4.22 (m, 2H, H-3’, H-5’), 4.08 – 4.06 (m, 1H, H-4’), 3.93 – 
3.89 (m, 2H, 2 x NHCHCH3), 1.87 – 1.84 (m, 4H, 2 x CH2-cyclohexyl), 1.77 – 1.74 
(m, 4H, 2 x CH2-cyclohexyl), 1.58 – 1.56 (m, 2H, CH2-cyclohexyl), 1.48 – 1.33 (m, 
16H, 5 x CH2-cyclohexyl, 2 x NHCHCH3); 13C NMR (125 MHz, CD3OD)μ δ = 175.64 
(d, 3JC-P = 5.37 Hz, C=O, ester), 167.69 (C-2), 157.79 (C-4), 142.66 (C-6), 123.66 
(apparent t, 1JC-F = 259 Hz, CF2), 96.85 (C-5), 86.00 (apparent t, broad signal, 2JC-F = 
30 Hz, C-1’), 80.48 (apparent t, 3JC-F = 8.50 Hz, C-4’), 74.66, 74.56 (2 x CH-
cyclohexyl), 71.29 (apparent t, 2JC-F = 25.0 Hz, C-3’), 64.54 (d, 2JC-P = 4.23 Hz, C-5’), 
51.13 (d, 2JC-P = 13.0 Hz, NHCHCH3), 32.55, 32.53, 32.48, 32.34, 26.58, 26.44, 24.79, 
24.69 (CH2-cyclohexyl), 21.15 (d, 3JC-P = 5.52 Hz, NHCHCH3), 20.93 (d, 3JC-P = 5.52 
Hz, NHCHCH3); MS [ES+] m/z: found 650.28 [M + H+], 672.26 [M + Na+], 
C27H42F2N5O9P required 649.62 [M].  Reverse-phase HPLC eluting with H2O/CH3CN 
from 100/0 to 0/100 in 35 min, F = 1 mL/min, Ȝ = 254, tR = 17.72 min. 
 
5-Fluoro-2′-deoxyuridine-5′-O-bis(2,2-dimethylpropoxy-L-alaninyl) phosphate  
(11): Prepared according to the standard procedure A from FUdR (0.25 g, 1.01 mmol), 
POCl3 (0.18 mL, 2.03 mmol), the tosylate salt of 2,2-dimethylpropoxy-L-alanine (1.68 
g, 5.07 mmol) and DIPEA (1.77 mL, 10.15 mmol).  After work-up and silica gel column 
chromatography phosphorodiamidate 11 was obtained as an off-white solid (0.020 g, 
3%). 31P NMR (202 MHz, CD3OD)μ δ = 13.94; 19F NMR (470 MHz, CD3OD)μ δ  = –
167.40; 1H NMR (500 MHz, CD3OD)μ δ = 7.86 (d, J = 6.2 Hz, 1H, H-6), 6.35 (t, J = 
5.2 Hz, 1H, H-1′), 4.48 – 4.45 (m, 1H, H-3′), 4.26 – 4.20 (m, 2H, H-5′), 4.18 – 4.15 (m, 
1H, H-4′), 4.08 – 4.00 (m, 2H, 2 x NHCHCH3), 3.86 – 3.78 (m, 4H, 2 x CH2C(CH3)3), 
2.38 – 2.35 (m, 1H, H-2′), 2.33 – 2.29 (m, 1H, H-2′), 1.48 – 1.43 (m, 6H, 2 x 
NHCHCH3), 1.00 (s, 18H, 2 x CH2C(CH3)3); 13C NMR (125 MHz, CD3OD)μ δC 175.6 
(d, 3JC–P = 3.7 Hz, C=O, ester), 159.8 (d, 2JC–F = 25.0 Hz, C-4), 151.0 (C-2), 141.7 (d, 
1JC–F = 232.5 Hz, C-5), 125.9 (d, 2JC–F = 33.75 Hz, C-6), 86.8 (C-1′), 86.6 (d, 3JC – P = 
8.75 Hz, C-4′), 75.4, 75.3 (CH2C(CH3)3), 71.9 (C-3′), 66.4 (d, 2JC–P = 5.0 Hz, C-5′), 
51.2 (d, 2JC–P = 7.5 Hz, CHCH3), 40.7 (C-2′), 32.4 (CH2C(CH3)3), 26.8 (CH2C(CH3)3), 
20.7, (2 x d, 3JC–P = 5.0 Hz, NHCHCH3). MS [ES+] m/z: found 631.64 [M + Na+], 
C25H42FN4O10P required 608.59 [M]. Reverse HPLC, eluting with H2O/CH3OH from 
100/0 to 0/100 in 30 min, F = 1 mL/min, Ȝ = 254, tR = 22.59. 
 
5-Fluoro-2′-deoxyuridine-5′-O-bis(pentoxy-L-alaninyl) phosphate (12): Prepared 
according to the standard procedure A from FUdR (0.35 g, 1.42 mmol), POCl3 (0.26 
mL, 2.84 mmol), the tosylate salt of pentoxy-L-alanine (1.39 g, 7.10 mmol) and DIPEA 
(2.47 mL, 14.20 mmol).  After work-up and silica gel column chromatography 
phosphorodiamidate 12 was obtained as an off-white solid (0.050 g, 6%). 31P NMR 
(202 MHz, CD3OD)μ δ = 13.91; 19F NMR (470 MHz, CD3OD)μ δ  = –167.35; 1H NMR 
(500 MHz, CD3OD)μ δ = 7.90 (d, J = 6.2 Hz, 1H, H-6), 6.30 (t, J = 5.5 Hz, 1H, H-1′), 
4.49 – 4.45 (m, 1H, H-3′), 4.20 – 4.15 (m, 7H, 2 x OCH2, 2 x H-5′, H-4′), 3.90 – 3.85 
(m, 2H, 2 x NHCHCH3), 2.38 – 2.35 (m, 1H, H-2′), 2.29 – 2.20 (m, 1H, H-2′), 1.72 – 
1.60 (m, 4H, 2 x CH2), 1.43 – 1.30 (m, 14H, 4 x CH2, 2 x NHCHCH3), 1.00 – 0.96 (m, 
6H, 2 x CH2CH3); 13C NMR (125 MHz, CD3OD)μ δ = 175.70, 175.67 (2d, 3JC–P = 3.7 
Hz, C=O, ester), 160.10 (d, 2JC–F = 26.0 Hz, C-4), 151.30 (C-2), 141.78 (d, 1JC–F = 235.0 
Hz, C-5), 125.85 (d, 2JC–F = 35.0 Hz, C-6), 86.90 (C-1′), 86.78 (d, 3JC–P = 7.5 Hz, C-4′), 
71.95 (C-3′), 66.48, 66.47 (OCH2), 66.38 (d, 2JC–P = 5.0 Hz, C-5′), 51.15, 50.64 (2d, 
2JC–P = 8.5 Hz, NHCHCH3), 40.79 (C-2′), 29.43, 29.20 (CH2), 23.61, 23.40 (CH2), 
20.95, 20.26 (2 x d, 3JC–P = 6.25 Hz, NHCHCH3). MS [ES+] m/z: found 631.59 [M + 
Na+], C25H42FN4O10P required 608.59 [M]. Reverse HPLC, eluting with H2O/CH3CN 
from 100/0 to 0/100 in 30 min, F = 1 mL/min, Ȝ = 254, tR = 15.88. 
 
5-Fluoro-2′-deoxyuridine-5′-O-bis(cyclopentoxy-L-alaninyl) phosphate (13): 
Prepared according to the standard procedure A from FUdR (0.35 g, 1.42 mmol), POCl3 
(0.26 mL, 2.84 mmol), the tosylate salt of cyclopentoxy-L-alanine (2.34 g, 7.10 mmol) 
and DIPEA (2.47 mL, 14.20 mmol).  After work-up and silica gel column 
chromatography phosphorodiamidate 13 was obtained as an off-white solid (0.075 g, 
9%). 31P NMR (202 MHz, CD3OD)μ δ = 13.99; 19F NMR (470 MHz, CD3OD)μ δ = –
167.47; 1H NMR (500 MHz, CD3OD)μ δ = 8.00 (d, J = 6.5 Hz, 1H, H-6), 6.26 (t, J = 
5.5 Hz, 1H, H-1′), 5.24 – 5.15 (m, 2H, OCH), 4.48 – 4.45 (m, 1H, H-3′), 4.32 – 4.29 
(m, 2H, H-5′), 4.15 – 4.08 (m, 1H, H-4′), 3.95 – 3.86 (m, 2H, 2 x NHCHCH3), 2.38 – 
2.35 (m, 1H, H-2′), 2.29 – 2.24 (m, 1H, H-2′), 2.00 – 1.89 (m, 4H, 2 x CH2), 1.72 – 1.59 
(m, 10H, 5 x CH2), 1.59 – 1.52 (m, 2H, CH2), 1.48 – 1.30 (m, 6H, 2 x NHCHCH3); 13C 
NMR (125 MHz, CD3OD)μ δ = 175.45, 175.41 (2d, 3JC–P = 2.5 Hz, C=O, ester), 159.76 
(d, 2JC F = 25.0 Hz, C-4), 151.06 (C-2), 142.0 (d, 1JC–F = 232.5 Hz, C-5), 125.95 (d, 2JC–
F = 34.0 Hz, C-6), 86.86 (C-1′), 86.78 (d, 3JC–P = 7.5 Hz, C-4′), 79.50 (OCH), 71.95 (C-
3′), 66.42 (d, 2JC–P = 5.0 Hz, C-5′), 51.20, 50.80 (2d, 2JC–P = 8.5 Hz, NHCHCH3), 40.75 
(C-2′), 33.84, 33.70, 33.52, 33.49 (CH2), 24.70, 24.69 (CH2), 20.94, 20.85 (2d, 3JC–P = 
6.25 Hz, CHCH3). MS [ES+] m/z: found 627.222 [M + Na+], C25H38FN4O10P, required 
604.56 [M]. HRMS [ESI] m/z: calculated for C25H38FN4O10P: 604.2310; found 
605.2314 [M + H]+.  Reverse HPLC, eluting with H2O/CH3CN from 100/0 to 0/100 in 
30 min, F = 1 mL/min, Ȝ = 254, tR = 13.39. 
 
5-Fluoro-2′-deoxyuridine-5′-O-bis(benzoxy-L-alaninyl) phosphate (14): Prepared 
according to the standard procedure A from FUdR (0.25 g, 1.01 mmol), POCl3 (0.18 
mL, 2.03 mmol), the tosylate salt of benzoxy-L-alanine (1.78 g, 5.07 mmol) and DIPEA 
(1.76 mL, 10.15 mmol). After work-up and silica gel column chromatography 
phosphorodiamidate 14 was obtained as an off-white solid (0.030 g, 5%). 31P NMR 
(202 MHz, CD3OD): δ =13.82; 19F NMR (470 MHz, CD3OD): δ  = –167.51; 1H NMR 
(500 MHz, CD3OD): δ = 7.90 (d, J = 6.5 Hz, 1H, H-6), 7.38 – 7.31 (m, 10 H, Ar-H), 
6.25 – 6.22 (m, 1H, H-1′), 5.22 – 5.10 (m, 4H, 2 x CH2Ph), 4.39 – 4.36 (m, 1H, H-3′), 
4.16 – 4.07 (m, 2H, H-5′), 4.01 – 3.95 (m, 3H, H-4′, 2 x NHCHCH3), 2.31 – 2.26 (m, 
1H, H-2′), 2.20 – 2.14 (m, 1H, H-2′), 1.42 – 1.34 (m, 6H, 2 x NHCHCH3); 13C NMR 
(125 MHz, CD3OD): δC = 175.3 (C=O, ester), 159.3 (C-4), 150.5 (C-2), 141.5 (d, 1JC–F 
= 238.0 Hz, C-5), 137.3, 137.1 (2 x C ipso-Ph), 129.7, 129.6, 129.5, 129.4, 129.3, 129.2, 
128.0 (CH-Ar), 125.8 (d, 2JC–F = 33.75 Hz, C-6), 122.5, 116.3 (CH-Ar), 86.8 (C-1′), 
86.7 (d, 3JC–P = 8.7 Hz, C-4′), 71.3 (C-3′), 68.0, 67.9 (CH2Ph), 66.4 (d, 2JC–P = 5.0 Hz, 
C-5′), 51.2, 51.1 (NHCHCH3), 40.7 (C-2′), 20.7, 20.6 (2 x d, 3JC–P = 6.2 Hz, 
NHCHCH3). MS [ES+] m/z: found 671.20 [M + Na+], C29H34FN4O10P required 648.57 
[M]. Reverse HPLC, eluting with H2O/CH3CN from 100/0 to 0/100 in 30 min, F = 1 
mL/min, Ȝ = 254, tR = 13.88. 
 
8-Chloroadenosine 5’-O-bis(benzoxy-L-alaninyl)phosphate (15): Prepared 
according to the general procedure A, using 8-chloroadenosine (0.25 g, 0.83 mmol), in 
(CH3O)3PO (5 mL), POCl3 (77 L, 0.83 mmol), L-alanine-O-benzyl ester tosylate salt 
(1.46 g, 4.15 mmol) in CH2Cl2 (5 mL) and DIPEA (1.45 mL, 8.3 mmol). The crude was 
purified by column chromatography (gradient elution of 4-7% CH3OH/CH2Cl2) to give 
the title compound 15 as a white solid (0.24 g, 42%).31P NMR (202 MHz, CD3OD)μ δ 
= 13.54; 1H NMR (500 MHz, CD3OD)μ δ = 8.21 (s, 1H, H-2), 7.36 – 7.26 (m, 10H, H-
Ph), 6.02 (d, J = 4.8 Hz, 1H, H-1’), 5.30 (t, J = 5.5 Hz, 1H, H2’), 5.14 – 5.02 (m, 4H, 2 
x CH2Ph), 4.62 (dd, J = 7.5, 5.0 Hz, 1H, H-3’), 4.31 – 4.24 (m, 1H, H-5’), 4.18 – 4.11 
(m, 2H, H-5’, H-4’), 3.95-3.82 (m, 2H, NHCHCH3), 1.28 (d, J = 7.2 Hz, 3H, CHCH3), 
1.23 (d, J = 7.2 Hz, 3H, CHCH3);13C NMR (125 MHz, CD3OD)μ δ = 175.34 (d, 3JC-P= 
5.0 Hz, C=O), 175.30 (d, 3JC-P= 5.0 Hz, C=O), 156.35 (C-6), 154.22 (C-2), 151.71 (C-
4), 139.83 (C-Ar), 137.32 (C-Ar), 137.27 (C-Ar), 129.58 (CH-Ar), 129.56 (CH-Ar), 
129.32 (CH-Ar), 129.28 (CH-Ar), 119.55 (C-5), 91.28 (C-1’), 84.50 (d, 3JC-P= 7.3 Hz, 
C-4’), 72.65 (C-2’), 71.47 (C-3’), 67.91 (CH2Ph), 67.86 (CH2Ph), 66.17 (d, 2JC-P= 4.4 
Hz, C-5’), 51.01 (NHCHCH3), 50.98 (NHCHCH3), 20.81 (d, 3JC-P= 6.0 Hz, 
NHCHCH3), 20.53 (d, 3JC-P= 6.0 Hz, NHCHCH3). MS [ES+] m/z: found 704.1 [M + 
H+], 726.1 [M + Na+], C30H35ClN7O9P required 704.07 [M]. HRMS [ESI+] m/z: 
calculated for C30H35ClN7O9P: 703.1922; found 704.0612 [M + H]+. Reverse-phase 
HPLC eluting with H2O/CH3CN from λ0/10 to 0/100 in 35 minutes, F = 1 mL/min, Ȝ 
= 254, tR 24.98 min.  
 
8-Chloroadenosine 5’-O-bis(benzoxy-glycinyl) phosphate (16): Prepared according 
to the general procedure A, using 8-chloroadenosine (0.10 g, 0.33 mmol), in 
(CH3O)3PO (2.5 mL), POCl3 (31 µL, 0.33 mmol), glycine-O-benzyl ester 
hydrochloride salt (0.33 g, 1.65 mmol), in CH2Cl2 (5 mL) and DIPEA (0.57 mL, 3.3 
mmol). The crude was purified by column chromatography (gradient elution of 4-7% 
CH3OH in CH2Cl2) to give the title compound as a white solid (0.06 g, 27%). 31P NMR 
(202 MHz, CD3OD)μ δ = 15.96; 1H NMR (500 MHz, CD3OD)μ δ = 8.23 (s, 1H, H2), 
7.35 – 7.26 (m, 10H, H-Ph), 6.03 (d, J = 5.1 Hz, 1H, H-1’), 5.31 (dd, J = 5.5, 5.1 Hz, 
1H, H-2’), 5.11 – 5.08 (m, 4H, 2 x CH2Ph), 4.59 (dd, 5.5 Hz, 5.1 Hz, 1H, H-3’), 4.34 – 
4.28 (m, 1H, H-5’), 4.27 – 4.16 (m, 2H, H-5’, H-4’), 3.70 – 3.64 (m, 4H, 2 x NHCH2); 
13C NMR (125 MHz, CD3OD)μ δ = 172.91 (d, 3JC-P= 4.7 Hz, C=O), 172.89 (d, 3JC-P= 
4.7 Hz, C=O), 156.24 (C6), 154.08 (C-2), 151.69 (C-4), 139.88 (C-Ar), 137.22 (C-Ar), 
129.57 (CH-Ar), 129.56 (CH-Ar), 129.33 (CH-Ar), 129.31 (CH-Ar), 119.56 (C-5), 
91.16 (C-1’), 84.70 (d, 3JC-P= 7.2 Hz, C-4’), 72.62 (C-2’), 71.58 (C-3’), 67.86 (CH2Ph), 
67.84 (CH2Ph), 66.17 (d, 2JC-P= 4.6 Hz, C-5’), 43.56 (NHCH2), 43.47 (NHCH2). MS 
[ES+] m/z: found 704.1 [M + H+], 726.1 [M + Na+], C28H31ClN7O9P required 676.01 
(M). Reverse-phase HPLC eluting with H2O/CH3CN from 90/10 to 0/100 in 35 
minutes, F = 1 mL/min, Ȝ = 254, tR 23.23 min. 
 
2-Fluoroadenine-9--D-arabinofuranoside-5′-O-bis(2,2-dimethylpropoxy-L-
alaninyl) phosphate (17): Prepared according to the standard procedure A from 
fludarabine (0.25 g, 0.88 mmol), POCl3 (0.16 mL, 1.75 mmol), the tosylate salt of 2,2-
dimethylpropoxy-L-alanine (1.45 g, 4.38 mmol) and DIPEA (1.52 mL, 8.76 mmol). 
After work-up and silica gel column chromatography phosphorodiamidate 17 was 
obtained as an off-white solid (0.052 g, 9%). 31P NMR (202 MHz, CD3OD)μ δ = 13.84; 
19F NMR (470 MHz, CD3OD)μ δ = –53.28; 1H NMR (500 MHz, CD3OD)μ δ = 8.25 (s, 
1H, H-8), 7.40 – 7.20 (m, 10 H, Ar-H), 6.32 (d, J = 4.3 Hz, 1H, H-1′), 4.46 – 4.25 (m, 
4H, H-2, H-3, 2 x H-5), 4.20 – 4.15 (m, 1H, H-4), 3.98 – 3.94 (m, 2H, 2 x 
NHCHCH3), 3.87, 3.84 (AB system, JAB = 10.5 Hz, 2H, CH2C(CH3)3), 3.74, 3.72 (AB 
system, JAB = 10.5 Hz, 2H, CH2C(CH3)3), 1.44 – 1.39 (m, 6H, 2 x NHCHCH3), 0.99 (s, 
18H, CH2C(CH3)3); 13C NMR (125 MHz, CD3OD)μ δ = 175.74, 175.66 (2d, 3JC–P = 5.0 
Hz, C=O, ester), 160.70 (d, 1JC–F = 207.5 Hz, C-2), 158.90 (d, 3JC–F = 20.0 Hz, C-6), 
152.26 (d, 3JC–F = 18.8 Hz, C-4), 142.69 (C-8), 117.84 (d, 4JC–F = 3.75 Hz, C-5), 86.07 
(C-1′), 84.06 (d, 4JC–P = 7.5 Hz, C-3), 77.31, 77.15 (C-2, C-4), 75.42 (CH2C(CH3)3), 
66.35 (d, 2JC–P = 5.0 Hz, C-5′), 51.2 (d, 2JC–P = 8.75 Hz, CHCH3), 32.34, 32.32 
(CH2C(CH3)3), 26.82 (CH2C(CH3)3), 21.15 (d, 3JC–P = 6.30 Hz, NHCHCH3), 21.02 (d, 
3JC–P = 6.30 Hz, NHCHCH3). [ES+] m/z: found 670.61 [M + Na+], C26H43FN7O9P 
required 647.63 [M]. HRMS [ESI+] m/z: calculated for C26H43FN7O9P: 647.2844 found 
647.2839 [M + H]+. Reverse HPLC, eluting with H2O/CH3OH from 100/0 to 0/100 in 
30 min, F = 1 mL/min, Ȝ = 254, tR = 25.52. 
 
2-Fluoroadenine-9--D-arabinofuranoside-5′-O-bis(benzoxy-L-alaninyl) 
phosphate (18): Prepared according to the standard procedure A from fludarabine 
(0.25 g, 0.88 mmol), POCl3 (0.16 mL, 1.75 mmol), the tosylate salt of benzoxy-L-
alanine (1.50 g, 4.38 mmol) and DIPEA (1.52 mL, 8.76 mmol). After work-up and 
silica gel column chromatography phosphorodiamidate 18 was obtained as an off-white 
solid (0.016g, 3%). 31P NMR (202 MHz, CD3OD): δ = 13.76; 19F NMR (470 MHz, 
CD3OD): δ = –53.30; 1H NMR (500 MHz, CD3OD): δ = 8.25 (s, 1H, H-8), 7.40 – 7.20 
(m, 10 H, Ar-H), 6.32 (d, J = 4.4 Hz, 1H, H-1′), 5.22 – 5.15 (m, 4H, 2 x CH2Ph), 4.40 
– 4.36 (m, 1H, H-2), 4.32 – 4.24 (m, 3H, 2 x H-5, H-4), 4.19 – 4.00 (m, 1H, H-3′), 
3.98 – 3.94 (m, 2H, NHCHCH3), 1.45 – 1.38 (m, 6H, 2 x NHCHCH3); 13C NMR (125 
MHz, CD3OD): δ = 175.56, 175.48 (2d, 3JC–P = 5.0 Hz, C=O, ester), 160.60 (d, 1JC–F = 
207.5 Hz, C-2), 158.85 (d, 3JC–F = 20.0 Hz, C-6), 152.18 (d, 3JC–F = 20.0 Hz, C-4), 
142.69 (C-8), 137.26, 137.21 (2 x C ipso-Ph), 129.86, 129.63, 129.61, 129.38, 129.33, 
129.32, 129.29, 129.25 (CH-Ar), 117.86 (C-5), 86.02 (C-1′), 83.96 (d, 4JC–P = 7.5 Hz, 
C-3), 77.25 (C-4), 77.15 (C-2), 67.98, 67.85 (CH2Ph), 66.30 (d, 2JC–P = 5.0 Hz, C-
5′), 51.2 (d, 2JC–P = 8.75 Hz, NHCHCH3), 20.85 (d, 3JC–P = 6.30 Hz, NHCHCH3), 20.72 
(d, 3JC–P = 6.30 Hz, NHCHCH3). [ES+] m/z: found 710.22 [M + Na+] C30H35FN7O9P 
required 687.61 [M]. Reverse HPLC, eluting with H2O/CH3OH from 100/0 to 0/100 in 
30 min, F = 1 mL/min, Ȝ = 254, tR = 23.08. 
 
Guanine-9--D-arabinofuranoside-5’-O-bis(2,2-dimethoxypropoxy-L-alaninyl) 
phosphate (19): Prepared according to general procedure A from AraG (0.40 g, 1.41 
mmol), POCl3 (0.216 g, 0. , the tosylate salt of 2,2-dimethoxypropoxy-L-
alanine (2.33 g, 7.05 mmol) and DIPEA (2.45 mL, 14.1 mmol). After the reaction was 
completed the solvent was removed under vacuum and the crude material was purified 
by column chromatography on silica gel followed by preparative HPLC (reverse-phase 
HPLC eluting with H2O/CH3CN from 90/10 to 0/100 in 20 minutes, F = 20 
= 254 nm, tR = 10.72 min) to afford phosphorodiamidate 19 as a white solid (0.050 g, 
6%). 31P NMR (202 MHz, CD3OD)μ δ = 13.88; 1H NMR (500 MHz, CD3OD)μ δH 7.90 
(s, 1H, H-8), 6.37 (d, J = 4.6 Hz, 1H, H-1), 4.33 – 4.27 (m, 4H, 2 x H-5, H-4, H-
2), 4.07 – 4.05 (m, 2H, H-3), 3.99 – 3.95 (m, 2H, 2 x NHCHCH3), 3.88, 3.78 (AB 
system JAB = 10.50 Hz, 2H, CH2C(CH3)3), 3.87, 3.77 (AB system, JAB = 10.50 Hz, 2H, 
CH2C(CH3)3), 1.42 (d, J = 7.5 Hz, 3H, NHCHCH3), 1.40 (d, J = 7.5 Hz, 3H, 
NHCHCH3), 0.98 (s, 18H, CH2C(CH3)3); 13C NMR (125 MHz, CD3OD)μ δ = 175.70, 
175.65 (C=O, ester), 159.35 (C-6), 155.36 (C-2), 152.99, (C-4), 139.61 (C-8), 117.09 
(C-5), 85.82 (C-1), 84.00 (d 3JC-P = 7.36 Hz, C-4), 77.59 (C-2), 77.25 (C-3), 75.39, 
75.37 (CH2C(CH3)3, 66.49 (d, 2JC-P = 5.26 Hz, C-5), 51.14 (CHCH3), 32.31 
(CH2C(CH3)3), 26.66 (CH2C(CH3)3), 21.09 (d, 3JC-P = 5.97 Hz, NHCHCH3), 20.95 (d, 
3JC-P = 6.44 Hz, NHCHCH3); MS [ES+] m/z: found 646 [M + H+], 669 [M + Na+], 
C26H44N7O10P required: 645.28 (M). HRMS [ESI+] m/z: calculated for C26H44N7O10P: 
645.2887; found 646.2881 [M + H]+. HPLC Reverse-phase HPLC eluting with 
H2O/CH3 tR = 14.93 
min. 
 
6-Thioinosine-5′-O-bis(benzoxy-L-alaninyl) phosphate (20): Prepared according to 
the standard procedure A from 6-thioinosine (0.15 g, 0.53 mmol), POCl3 (0.05 mL, 
0.53 mmol), the tosylate salt of benzoxy-L-alanine (0.88 g, 2.50 mmol) and DIPEA 
(0.91 mL, 5.01 mmol). After work-up and silica gel column chromatography 
phosphorodiamidate 20 was obtained as an off-white solid (0.014 g, 4%). 31P NMR 
(202 MHz, CD3OD)μ δ = 13.71; 1H NMR (500 MHz, CD3OD)μ δ = 8.40 (s, 1H, H-2), 
8.15 (s, 1H, H-8), 7.35 – 7.29 (m, 10 H, Ar-H), 6.01 (d, J = 4.5 Hz, 1H, H-1′), 5.15, 
5.13, 5.10, 5.07 (2 x AB system, JAB = 12.5, 4.5 Hz, 4H, 2 x CH2Ph), 4.70 (t, J = 4.5 
Hz, 1H, H-2’), 4.40 (t, J = 4.5 Hz, 1H, H-3), 4.25 – 4.14 (m, 3H, 2 x H-5, H-4), 3.94 
– 3.91 (m, 2H, 2 x NHCHCH3), 1.32, 1.29 (2 x d, J = 7.0 Hz, 2 x NHCHCH3); 13C 
NMR (125 MHz, CD3OD)μ δ = 178.27 (C=S), 175.44, 175.38 (2d, 3JC–P = 5.0 Hz, C=O, 
ester), 145.03 (C-2), 142.90 (C-4), 142.80 (C-8), 137.31, 137.27 (2 x C ipso-Ph), 137.05 
(C-5), 129.58, 129.57, 129.31, 129.30, 127.17 (CH-Ar), 90.42 (C-1′), 84.74, 84.70 (d, 
3JC–P = 8.2 Hz, C-4), 75.53 (C-2), 71.57 (C-3’), 67.99, 67.96 (CH2Ph), 66.22, 66.18 
(C-5′), 51.14, 51.10 (d, 2JC–P = 6.25 Hz, NHCHCH3), 20.85 (d, 3JC–P = 6.25 Hz, 
NHCHCH3), 20.62 (d, 3JC–P = 6.30 Hz, NHCHCH3). [ES+] m/z: found 709.71 [M + 
Na+] C30H35N6O9PS required 686.67 [M].  
 
6-Thioinosine-5′-O-bis(2,2-dimethoxypropoxy-L-alaninyl)phosphate (21): 
Prepared according to the standard procedure A from 6-thioinosine (0.15 g, 0.53 mmol), 
POCl3 (0.05 mL, 0.53 mmol), the tosylate salt of 2,2-dimethoxypropoxy-L-alanine 
(0.87 g, 2.50 mmol) and DIPEA (0.91 mL, 5.01 mmol). After work-up and silica gel 
column chromatography phosphorodiamidate 21 was obtained as an off-white solid 
(0.017 g, 5%). 31P NMR (202 MHz, CD3OD)μ δ = 13.84; 1H NMR (500 MHz, CD3OD): 
δ
 
=
 
8.43 (s, 1H, H-2), 8.19 (s, 1H, H-8), 6.04 (d, J = 5.0 Hz, 1H, H-1′), 4.72 (t, J = 5.0 
Hz, 1H, H-2’), 4.43 (t, J = 5.0 Hz, 1H, H-3), 4.30 – 4.21 (m, 3H, 2 x H-5, H-4), 3.97 
– 3.93 (m, 2H, 2 x NHCHCH3), 3.88, 3.86, 3.76, 3.74 (2 x AB system, JAB = 10.5, 4.5 
Hz, 4H, 2 x CH2C(CH3)3), 1.39, 1.37 (2 x d, J = 7.0 Hz, 2 x NHCHCH3), 0.95 (s, 18H, 
2 x CH2C(CH3)3);  13C NMR (125 MHz, CD3OD)μ δ = 178.44 (C=S), 175.07, 175.02 
(2d, 3JC–P = 6.25 Hz, C=O, ester), 146.47 (C-2), 145.03 (C-4), 142.76 (C-8), 137.19 (C-
5), 90.44 (C-1′), 84.82, 84.76 (d, 3JC–P = 7.8 Hz, C-4), 79.47 (CH2C(CH3)3), 74.89 (C-
2), 71.58 (C-3’), 66.27, 66.23 (d, 2JC–P = 5.0 Hz, C-5′), 51.19, 51.09 (d, 2JC–P = 6.0 Hz, 
NHCHCH3), 32.53, 32.50, 32.46, 32.44 (CH2C(CH3)3), 30.73, 26.44, 24.67 
(CH2C(CH3)3), 21.13 (d, 3JC–P = 5.6 Hz, NHCHCH3), 20.89 (d, 3JC–P = 5.60 Hz, 
NHCHCH3). [ES+] m/z: found 669.83 [M + Na+] C26H43N6O9PS required 646.69 [M]. 
 
6-Thioguanosine-5′-O-bis(benzoxy-L-alaninyl) phosphate (22): Prepared according 
to the standard procedure A from 6-thioguanosine (0.15 g, 0.50 mmol), POCl3 (0.05 
mL, 0.53 mmol), the tosylate salt of benzoxy-L-alanine (0.88 g, 2.50 mmol) and DIPEA 
(0.91 mL, 5.01 mmol). After work-up and silica gel column chromatography 
phosphorodiamidate 22 was obtained as an off-white solid (0.010 g, 3%). 31P NMR 
(202 MHz, CD3OD)μ δ = 13.70; 1H NMR (500 MHz, CD3OD)μ δ = 8.15 (s, 1H, H-8), 
7.35 – 7.30 (m, 10 H, Ar-H), 6.01 (d, J = 5.5 Hz, 1H, H-1′), 5.16 –5.06 (m, 4H, 2 x 
CH2Ph), 4.68 (t, J = 5.5 Hz, 1H, H-2’), 4.48 (t, J = 5.5 Hz, 1H, H-3), 4.24 – 4.20 (m, 
1H, 1 x H-5), 4.16 – 4.14 (m, 2H, 1 x H-5H-4), 3.97 – 3.91 (m, 2H, 2 x 
NHCHCH3), 1.32, 1.29 (2 x d, J = 7.0 Hz, 2 x NHCHCH3); 13C NMR (125 MHz, 
CD3OD)μ δ = 177.12 (C=S), 175.44, 175.38 (2d, 3JC–P = 6.25 Hz, C=O, ester), 163.19 
(C-2), 161.34 (C-4), 151.47 (C-8), 140.49 (C-5), 137.25, 137.20 (2 x C ipso-Ph), 
129.61, 129.37, 129.34, 129.32, 127.17 (CH-Ar), 90.02 (C-1′), 84.49, 84.41 (d, 3JC–P = 
8.2 Hz, C-4), 74.63 (C-2), 71.69 (C-3’), 68.07, 68.02 (CH2Ph), 66.38, 66.32 (d, 2JC–
P = 7.5 Hz, C-5′), 51.14, 51.08 (d, 2JC–P = 3.8 Hz, NHCHCH3), 20.85 (d, 3JC–P = 5.8  
Hz, NHCHCH3), 20.62 (d, 3JC–P = 5.80 Hz, NHCHCH3). [ES+] m/z: found 724.75 [M 
+ Na+] C30H36N7O9PS required 701.68 [M]. 
 
6-Thioguanosine-5′-O-bis(2,2-dimethoxypropoxy-L-alaninyl)phosphate (23): 
Prepared according to the standard procedure A from 6-thiguanosine (0.15 g, 0.50 
mmol), POCl3 (0.05 mL, 0.50 mmol), the tosylate salt of 2,2-dimethoxypropoxy-L-
alanine (0.83 g, 2.50 mmol) and DIPEA (0.91 mL, 5.01 mmol). After work-up and 
silica gel column chromatography phosphorodiamidate 23 was obtained as an off-white 
solid (0.016 g, 5%). 31P NMR (202 MHz, CD3OD)μ δ = 13.83; 1H NMR (500 MHz, 
CD3OD)μ δ = 8.05 (s, 1H, H-8), 5.87 (d, J = 5.0 Hz, 1H, H-1′), 4.71 (t, J = 5.0 Hz, 1H, 
H-2’), 4.41 (t, J = 5.0 Hz, 1H, H-3), 4.30 – 4.19 (m, 3H, 2 x H-5, H-4), 4.00 – 3.95 
(m, 2H, 2 x NHCHCH3), 3.88, 3.86, 3.76, 3.74 (2 x AB system, JAB = 10.5, 4.5 Hz, 4H, 
2 x CH2C(CH3)3), 1.38, 1.35 (2 x d, J = 7.0 Hz, 2 x NHCHCH3), 0.94 (s, 18H, 2 x 
CH2C(CH3)3);  13C NMR (125 MHz, CD3OD)μ δ = 177.1 (C=S), 175.66, 175.58 (2d, 
3JC–P = 5.8 Hz, C=O, ester), 164.19 (C-2), 148.82 (C-4), 140.71 (C-8), 130.28 (C-5), 
90.11 (C-1′), 84.70, 84.64 (d, 3JC–P = 7.5 Hz, C-4), 75.44 (CH2C(CH3)3), 75.41 (C-
2), 74.71 (C-3’), 66.56, 66.50 (d, 2JC–P = 7.70 Hz, C-5′), 51.17, 51.09 (d, 2JC–P = 10.0 
Hz, NHCHCH3), 32.38, 32.35 (CH2C(CH3)3), 26.79 (CH2C(CH3)3), 21.12, 21.10 (d, 
3JC–P = 5.6 Hz, NHCHCH3), 20.89 (d, 3JC–P = 5.60 Hz, NHCHCH3). [ES+] m/z: found 
684.78 [M + Na+] C26H44N7O9PS required 661.70 [M]. 
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